Incannex Secures U.S. Patent Extending IHL-42X Exclusivity Through 2040
IXHL•Incannex Healthcare has secured a U.S. patent for IHL-42X in obstructive sleep apnea, granting protection through July 2040 with potential for term extension. This milestone bolsters the company’s intellectual property ahead of Phase III development and supports long-term market exclusivity for its lead oral combination therapy.
1. U.S. Patent Grant for IHL-42X
Incannex Healthcare announced that the USPTO granted a patent titled “Compositions and Methods of Treatment for Obstructive Sleep Apnea,” providing IHL-42X protection through July 9, 2040, with potential patent term extension following FDA approval.
2. Clinical Development and Fast Track Status
IHL-42X holds FDA Fast Track designation and positive Phase II data from the RePOSA study. Incannex is nearing patient recruitment for the DReAMzz Phase II crossover dose optimisation trial after securing central and site-specific IRB approvals and DEA researcher registrations.
3. Commercial and Strategic Implications
The strengthened U.S. patent enhances long-term market exclusivity for IHL-42X, a novel oral combination therapy addressing an estimated one billion global OSA patients. This positions the asset for differentiated treatment and potential premium market share.
4. Next Steps in Development
Incannex is preparing additional patent filings to broaden IP coverage, reviewing development data to refine Phase III trial design, and advancing regulatory strategy to support IHL-42X’s safety, efficacy and commercial launch.
